Tumour Agnostic Precision Treatment
Appleglc.com leads tumour-agnostic oncology — covering larotrectinib, entrectinib, pembrolizumab MSI-H approvals, and biomarker-driven therapies transcending traditional cancer-type boundaries.
Keytruda
Pembrolizumab
Vitrakvi
Larotrectinib Sulfate
Rozlytrek
Entrectinib
Opdivo
Nivolumab
Tecentriq
Atezolizumab
Imfinzi
Durvalumab
Bavencio
Avelumab
Libtayo
Cemiplimab-rwlc
Loqtorzi
Toripalimab-tpzi
Tevimbra
Tislelizumab-jsgr
Opdualag
Nivolumab and Relatlimab-rmbw
Jemperli
Dostarlimab-gxly
Zynyz
Retifanlimab-dlwr
Krazati
Adagrasib
Lumakras
Sotorasib
Rybrevant
Amivantamab-vmjw
Retevmo
Selpercatinib
Gavreto
Pralsetinib
Augtyro
Repotrectinib
Tabrecta
Capmatinib
Tepmetko
Tepotinib
Pemazyre
Pemigatinib
Lytgobi
Futibatinib
Truseltiq
Infigratinib
Balversa
Erdafitinib
Afinitor
Everolimus
Torisel
Temsirolimus
Welireg
Belzutifan
Voranigo
Vorasidenib Citrate
Xospata
Gilteritinib Fumarate
Idhifa
Enasidenib Mesylate
Daurismo
Glasdegib Maleate
Revuforj
Revumenib Citrate
Koselugo
Selumetinib
Ogsiveo
Nirogacestat
Enhertu
Fam-Trastuzumab Deruxtecan-nxki
Kadcyla
Ado-trastuzumab Emtansine
Trodelvy
Sacituzumab Govitecan-hziy
Padcev
Enfortumab Vedotin
Elahere
Mirvetuximab Soravtansine-gynx